Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDepth of weight loss drug pipeline will support growth even as cost lowers, says StemPoint's RossMichelle Ross, StemPoint Capital CIO and Novo Nordisk shareholder, joins CNBC's 'Closing Bell' to discuss the criticism Novo has faced around high drug prices, the potential earnings impact if prices come down, and more.
Persons:
StemPoint's Ross Michelle Ross, Novo
Organizations:
StemPoint Capital, Novo Nordisk